Ultomiris (Ravulizumab-Cwv) for PNH

Overview
Ultomiris is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat people 1 month or older with paroxysmal nocturnal hemoglobinuria (PNH). Ultomiris is also referred to by its drug name, ravulizumab-cwvz.

Ultomiris is a complement inhibitor. This drug is a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Ultomiris is believed to work by binding to complement protein C5, part of the immune system that attacks red blood cells in PNH, and preventing it from being activated.

How do I take it?
Ultomiris is administered by IV infusion once every four or eight weeks, depending on body weight, after the initial loading dose. The medication is available as a single-dose vial.

Side effects
The FDA-approved label for Ultomiris lists common side effects including headache and upper respiratory tract infection.

Rare but serious side effects listed for Ultomiris include severe infusion reactions and increased risks of meningococcal infections (which affect the lining of the brain or spinal cord) and sepsis (a severe immune reaction to infection), both of which may be life-threatening or fatal.

For more details about this treatment, visit:

Ultomiris homepage — Alexion
https://ultomiris.com/pnh

Ravulizumab-Cwvz Injection — MedlinePlus
https://medlineplus.gov/druginfo/meds/a619014.h...